Change in systolic left ventricular performance after 3 years of antihypertensive treatment: The Losartan Intervention for Endpoint (LIFE) study
Diabetes Mellitus, Type 2
Hypertrophy, Left Ventricular
Antihypertensive therapy reduced LVM and increased LV midwall shortening and contractility with a small decrease in LV chamber function and significant increase in SV. Change in systolic LV performance was independently associated inversely with change in LVM, RWT, and BP and directly with change in SV.